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A B S T R A C T
Objectives: The results of the randomized phase 3 CREST trial evaluating the use of thoracic radiotherapy for
extensive-stage small-cell lung cancer (ES-SCLC) were published in the Lancet in 2015. The primary endpoint
(10% overall survival diﬀerence at 1-year) was not achieved, but there was signiﬁcant improvement in 2-year
overall survival (13% vs 3%; p=0.004) and low toxicity rates, suggesting thoracic radiotherapy should be
considered for ES-SCLC patients who respond to chemotherapy. Questions have been raised as to whether these
results will lead to a change in practice.
Materials and methods: We developed an electronic survey to determine the impact of the publication on clinical
practice across some European countries.
Results and conclusion: We report the results of our survey, which suggest the CREST trial has changed practice,
resulting in an increase in the use of thoracic radiotherapy amongst the surveyed centers from 25% to 85%.
Furthermore the dose and fractionation schedule used in the trial has been widely adopted across Europe.
Introduction
Most patients with small-cell lung cancer present with extensive-
stage disease and have a 2-year survival of less than 5%. Standard
treatment is four to six cycles of platinum-based chemotherapy, a re-
gime unchanged over recent decades. In an EORTC trial, prophylactic
cranial irradiation administered to those who have responded to che-
motherapy, reduced the incidence of symptomatic brain metastases by
over half and improved 1-year survival by 14% [1].
Persisting intrathoracic disease after completing chemotherapy is
common, with approximately 90% of patients presenting with in-
trathoracic progression within a year of diagnosis [1]. Therefore the
next logical step was to investigate the role of thoracic radiotherapy in
this group of patients.
The results of the randomized phase 3 CREST trial evaluating the
use of thoracic radiotherapy for extensive-stage small-cell lung cancer
(ES-SCLC) were published in 2015 [2]. The CREST study enrolled 495
patients from 42 centres, mainly in the Netherlands and United
Kingdom. The main eligibility criteria included Eastern Cooperative
Oncology Group (ECOG) scale performance status 0–2, conﬁrmed ES-
SCLC deﬁned as disease beyond the hemithorax, hilar, mediastinal and
supraclavicular nodes, any response after 4–6 cycles of platinum-based
chemotherapy without evidence of disease progression at any site; and
no clinical evidence of brain, leptomeningeal or pleural metastases.
Patients were randomly assigned (1:1) to either thoracic radiotherapy
(30 Gy in 10 fractions over two weeks) plus prophylactic cranial irra-
diation or prophylactic cranial irradiation only. Before randomization,
patients had a CT thorax and upper abdomen. Brain imaging with CT or
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MRI was also performed in any patient with symptoms suspicious for
brain metastases. The primary endpoint (10% overall survival diﬀer-
ence at 1-year) was not achieved, but there was signiﬁcant improve-
ment in 2-year overall survival (13% vs 3%; p=0.004), suggesting
thoracic radiotherapy should be considered for ES-SCLC patients who
respond to chemotherapy. Furthermore severe treatment-related toxi-
city was uncommon with 10.5% and 7.2% of patients developing grade
3 toxicity in the thoracic radiotherapy and the control group respec-
tively. These results have raised controversy regarding the im-
plementation of thoracic radiotherapy [3–9], which led to the devel-
opment of a survey in some European countries to determine the impact
of the publication on clinical practice.
Materials and methods
In May 2015, an electronic questionnaire (see Appendix 1) com-
prising 34 items was developed using publicly available software.
Questions included in the survey:
• Use of thoracic radiotherapy before and after the publication of the
CREST study results in diﬀerent clinical scenario (symptomatic re-
sidual disease, asymptomatic central residual disease, no central
disease)
• Practice of prophylactic cranial irradiation in ES-SCLC
• Reasons for not implementing thoracic radiotherapy
• Staging investigations performed
• Future research questions
One academic lead in radiation oncology per country circulated the
survey by email to all centres within their country. It was requested,
that when possible, one answer per centre was provided to reﬂect
practice within the centre rather than an individual clinician opinion.
The survey was distributed in 7 European countries.
Results
The survey received 95 responses (United Kingdom=42,
Belgium=18, Netherlands= 14, France= 8, Germany=7,
Switzerland=5, Poland=1) from 93 centres and was re-sent to non-
responders. The overall response to the survey was 66% (95/143). In
some centres it was not possible to provide a consensus, and therefore
in two centres more than one dose and fractionation regime was pro-
vided.
Thoracic radiotherapy
Before the publication of CREST only 24 (25%) centres delivered
thoracic radiotherapy routinely to patients who responded to che-
motherapy, compared to the current practice of 81 (85%). Three clin-
ical scenarios were provided to the surveyed centres with regards to
response to initial chemotherapy, see Table 1. The largest increase in
the use of thoracic radiotherapy was in patients with asymptomatic
residual thoracic disease after chemotherapy.
An upper limit of performance status (ECOG2) is applied to select
patients for thoracic radiotherapy in 54 (79%) centres.
Prior to the publication of the trial, thoracic radiotherapy dose
fractionation varied widely, but now the dose delivered in the experi-
mental arm of CREST (30 Gy in 10 fractions) is prescribed in 52 (69%)
centres, see Fig. 1.
In the 18 (18%) centres who did not implement thoracic radio-
therapy after the publication of the CREST trial, a variety of explana-
tions were given, including the primary endpoint of the study not being
met, or the diﬀerence in survival not being clinically meaningful, but no
single reason stood out.
Prophylactic cranial irradiation
In patients who have responded to chemotherapy, 92 (97%) centres
give prophylactic cranial irradiation routinely. Of these, 45 (49%) de-
liver 25 Gy in 10 fractions and 40 (43%) deliver 20 Gy in 5 fractions.
An upper age limit was applied in 30 (33%) centres for selection of
patients for prophylactic cranial irradiation. Most commonly an upper
age limit of 75 was applied in 18 (60%) centres.
An upper limit for performance status was applied in 81 (88%)
centres, most commonly ECOG 2.
Staging investigations
The practice that diﬀered most between centres was which routine
staging investigations were performed before chemotherapy. A com-
puted tomography (CT) thorax and abdomen was performed in 61
(64%) centres, CT thorax, abdomen and pelvis in 27 (28%) centres,
Positron Emission Tomography (PET) scan in 33 (35%) centres, ima-
ging of the brain (CT or MRI) in 55 (57%) centres and an Isotope bone
scan in 13 (14%) centres. Interestingly, in the United Kingdom CT/MRI
imaging of the brain was only performed in 8 (14%) centres compared
to 51 (86%) of centres outside the United Kingdom.
Future research
When asked which research question was most important to study
next in this group of patients, responses varied widely from adding
targeted agents/immunotherapy to thoracic radiotherapy, both in-
creasing the dose of thoracic radiotherapy and using radiotherapy and/
or SABR to treat metastatic sites and determining which patient groups
would beneﬁt from thoracic radiotherapy.
Discussion
Our results show an increase in the use of thoracic radiotherapy in
patients with ES-SCLC, suggesting the CREST trial has changed practice.
The largest increase was in patients with asymptomatic residual thor-
acic disease after chemotherapy. The dose and fractionation schedule
used in the trial has been widely adopted across Europe. The survey also
shows high consistency in European practice in the use of prophylactic
cranial irradiation. The staging procedures were very heterogeneous
with limited use of PET-CT and brain imaging, which can impact on the
outcome of these patients after thoracic radiotherapy.
A question raised in correspondence to the Lancet [7,9] following
the publication of CREST and from a number of the responders to our
questionnaire was which subgroups of patients will beneﬁt most from
thoracic radiotherapy in ES-SCLC. This has been initially addressed by
further analysis of patients in the CREST trial. In the trial, patients were
stratiﬁed by the presence or absence of intrathoracic disease after
chemotherapy and further analysis demonstrated a statistically sig-
niﬁcant overall survival beneﬁt in patients with residual intrathoracic
disease who received thoracic radiotherapy (hazard ratio 0.81, 95% CI
Table 1
Centres delivering thoracic radiotherapy routinely to patients who respond to
chemotherapy.
Pre CREST study
(n=24)
Post CREST study
(n=81)
Does your centre give thoracic
radiotherapy routinely? (n=95)
25% (24/95) 85% (81/95)
If thoracic RT applied, in which scenario is it used?
• Patients with symptomatic residual
disease
92% (22/24) 92% (74/80)
• Patients with asymptomatic central
residual disease
79% (19/24) 93% (75/81)
• Patients with no central disease 42% (10/24) 49% (40/81)
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0.66–1.00, p=0.044) [8]. Additional data on sites and number of
metastases has been collected from 260 patients across the top 9 re-
cruiting centres in the CREST trial (53% of the 495 study patients were
included) [10]. The overall survival (p=0.02) and progression free
survival (PFS) (p=0.04) were signiﬁcantly better in patients with 2 or
fewer metastases, with signiﬁcantly worse overall survival if liver
(p=0.03) and/or bone metastases (p=0.04) were present. The addi-
tional analysis suggests that future studies evaluating more intensive
thoracic and extra-thoracic radiotherapy in ES-SCLC should focus on
patients with fewer than 3 distant metastases.
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Appendix 1. Questionnaire
1. In which country do you practice?
2. Which centre are you from?
3. Did your centre take part in the REST study?
a) Yes
b) No
4. In patients with extensive stage small-cell lung cancer (ES-SCLC)
which staging investigations are routinely carried out before che-
motherapy?
a) CT thorax & abdomen
b) CT thorax, abdomen & pelvis
c) CT brain
d) MRI brain
e) Isotope bone scan
f) PET scan
g) Other, please specify
5. In patients with ES-SCLC which staging investigations are routinely
carried out after chemotherapy?
a) CT thorax & abdomen CT thorax & abdomen
b) CT thorax, abdomen & pelvis
c) CT brain
d) MRI brain
e) Isotope bone scan
f) PET scan
g) Other, please specify
6. Do you use prophylactic cranial irradiation (PCI) routinely in pa-
tients with ES-SCLC who have responded to chemotherapy?
a) Yes
b) No
7. What dose and fractionation do you use?
a) 20 Gy in 5 fractions
b) 25 Gy in 10 fractions
c) 30 Gy in 12 fractions
d) Other, please specify
8. Do you apply an upper age limit for PCI in ES-SCLC?
a) Yes
b) No
9. What is your upper age limit for PCI?
a) 70 years old
b) 75 years old
c) 80 years old
d) Other, please specify
10. Do you restrict the use of PCI in ES-SCLC based on performance
status?
a) Yes
b) No
11. What is your upper limit for performance status using ECOG?
a) 0
b) 1
c) 2
d) 3
e) Other, please specify
12. Before the publication of the (C)REST study did your centre give
thoracic radiotherapy routinely to patients who had responded to
chemotherapy?
a) Yes
b) No
13. Before the publication of the (C)REST study did your centre give
thoracic radiotherapy to patients who had responded to che-
motherapy with symptomatic residual disease?
a) Yes
b) No
14. What dose and fractionation did you use (symptomatic residual
disease)?
a) 20 Gy in 5 fractions
b) 30 Gy in 10 fractions
c) 40 Gy in 15 fractions
d) Other, please specify
15. Before the publication of the (C)REST study did your centre give
Fig. 1. Dose and fractionation used for ES-SCLC patients before and after the publication of the CREST study.
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thoracic radiotherapy to patients who had responded to che-
motherapy with asymptomatic central residual disease?
a) Yes
b) No
16. What dose and fractionation did you use (asymptomatic central
residual disease)?
a) Yes
b) No
17. Before the publication of the (C)REST study did your centre give
thoracic radiotherapy to asymptomatic patients who had responded
to chemotherapy with no central residual disease?
a) Yes
b) No
18. What dose and fractionation did you use (asymptomatic no central
residual disease)?
a) 20 Gy in 5 fractions
b) 30 Gy in 10 fractions
c) 40 Gy in 15 fractions
d) Other, please specify
19. Before the publication of the (C)REST study what was your pre-
ferred time interval between completion of chemotherapy and
starting thoracic radiotherapy?
a) 3 weeks
b) 4 weeks
c) 6 weeks
d) 8 weeks
e) Other, please specify
20. Since the publication of the (C)REST study does your centre use
thoracic radiotherapy to patients who have responded to che-
motherapy?
a) Yes
b) No
21. Since the publication of the (C)REST study does your centre give
thoracic radiotherapy to patients who have responded to che-
motherapy with symptomatic residual disease?
a) Yes
b) No
22. What dose and fractionation did you use (symptomatic residual
disease)?
a) 20 Gy in 5 fractions
b) 30 Gy in 10 fractions
c) 40 Gy in 15 fractions
d) Other, please specify
23. Since the publication of the (C)REST study does your centre give
thoracic radiotherapy to patients who have responded to che-
motherapy with asymptomatic central residual disease?
a) Yes
b) No
24. What dose and fractionation did you use (symptomatic residual
disease)?
a) 20 Gy in 5 fractions
b) 30 Gy in 10 fractions
c) 40 Gy in 15 fractions
d) Other, please specify
25. Since the publication of the (C)REST study does your centre give
thoracic radiotherapy to asymptomatic patients who have re-
sponded to chemotherapy with no central residual disease?
a) Yes
b) No
26. What dose and fractionation did you use (asymptomatic no central
residual disease)?
a) 20 Gy in 5 fractions
b) 30 Gy in 10 fractions
c) 40 Gy in 15 fractions
d) Other, please specify
27. In your current practice do you apply an upper age limit when
giving thoracic radiotherapy in ES-SCLC?
a) Yes
b) No
28. What is your upper age limit?
a) 70 years old
b) 75 years old
c) 80 years old
29. Do you restrict the use of thoracic RT in ES-SCLC based on per-
formance status?
a) Yes
b) No
30. What is your upper limit for performance status using ECOG?
a) 0
b) 1
c) 2
d) 3
e) Other, please specify
31. After the publication of the (C)REST study what is your preferred
time interval between completion of chemotherapy and starting
thoracic radiotherapy?
a) 3 weeks
b) 4 weeks
c) 6 weeks
d) 8 weeks
e) Other, please specify
32. If thoracic radiotherapy is not going to be implemented in your
centre following the publication of the (C)REST study, please tick if
any of the explanations apply below or we would be grateful if you
could expand using the free text?
a) Not applicable, my centre has implemented thoracic RT
b) Diﬀerence in survival not clinically meaningful
c) Primary endpoint of the study not met
d) Concerns regarding toxicity of thoracic radiotherapy
e) Conﬁrmatory trial needed before a change in practice is im-
plemented
f) Other, please specify
33. Following the publication of the (C)REST study which research
question do you think is most important in this group of patients?
a) Increasing the dose of thoracic radiotherapy
b) Using radiotherapy and/or SABR to treat metastatic sites
c) Both increasing the dose of thoracic radiotherapy and using
radiotherapy and/or SABR to treat metastatic sites
d) Delivery of thoracic radiotherapy concurrently with che-
motherapy
e) Addition of targeted agents/immunotherapy to thoracic radio-
therapy
f) Other, please specify
34. Please make any general comments on the use of thoracic radio-
therapy in patients who have responded to chemotherapy in ES-
SCLC, and/or any diﬃculties in answering the survey.
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